Entropy Technologies LP Acquires Shares of 4,200 Bio-Rad Laboratories, Inc. (NYSE:BIO)

Entropy Technologies LP acquired a new stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 4,200 shares of the medical research company's stock, valued at approximately $1,405,000.

A number of other institutional investors have also recently added to or reduced their stakes in BIO. US Bancorp DE grew its position in shares of Bio-Rad Laboratories by 13.8% in the first quarter. US Bancorp DE now owns 9,960 shares of the medical research company's stock valued at $3,445,000 after purchasing an additional 1,209 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its position in Bio-Rad Laboratories by 15.2% in the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 941 shares of the medical research company's stock worth $325,000 after purchasing an additional 124 shares in the last quarter. State Board of Administration of Florida Retirement System lifted its stake in Bio-Rad Laboratories by 4.3% during the first quarter. State Board of Administration of Florida Retirement System now owns 26,050 shares of the medical research company's stock worth $9,010,000 after purchasing an additional 1,076 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in Bio-Rad Laboratories by 10.2% during the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 22,850 shares of the medical research company's stock valued at $7,903,000 after purchasing an additional 2,113 shares in the last quarter. Finally, First Eagle Investment Management LLC grew its stake in shares of Bio-Rad Laboratories by 310.0% in the 1st quarter. First Eagle Investment Management LLC now owns 1,964 shares of the medical research company's stock valued at $679,000 after purchasing an additional 1,485 shares during the period. 65.24% of the stock is currently owned by institutional investors and hedge funds.

Bio-Rad Laboratories Price Performance

Shares of BIO traded down $12.97 during mid-day trading on Thursday, hitting $350.23. 148,088 shares of the company traded hands, compared to its average volume of 246,016. The company has a current ratio of 6.14, a quick ratio of 4.52 and a debt-to-equity ratio of 0.16. The stock has a market capitalization of $9.81 billion, a price-to-earnings ratio of -12.81 and a beta of 0.93. The business has a 50-day moving average of $340.67 and a 200 day moving average of $313.77. Bio-Rad Laboratories, Inc. has a one year low of $262.12 and a one year high of $387.99.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last announced its quarterly earnings data on Wednesday, October 30th. The medical research company reported $2.01 EPS for the quarter, topping analysts' consensus estimates of $1.16 by $0.85. Bio-Rad Laboratories had a positive return on equity of 3.74% and a negative net margin of 30.18%. The firm had revenue of $649.70 million during the quarter, compared to analyst estimates of $628.18 million. During the same period last year, the company earned $2.33 earnings per share. The company's revenue was up 2.8% on a year-over-year basis. As a group, equities analysts expect that Bio-Rad Laboratories, Inc. will post 9.93 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts recently commented on BIO shares. StockNews.com raised Bio-Rad Laboratories from a "hold" rating to a "buy" rating in a research note on Friday, November 1st. Citigroup upped their price objective on shares of Bio-Rad Laboratories from $400.00 to $450.00 and gave the stock a "buy" rating in a research note on Thursday, October 31st. Wells Fargo & Company initiated coverage on shares of Bio-Rad Laboratories in a research note on Tuesday, August 27th. They issued an "equal weight" rating and a $340.00 target price for the company. Finally, Royal Bank of Canada increased their price target on Bio-Rad Laboratories from $446.00 to $469.00 and gave the stock an "outperform" rating in a research report on Thursday, October 31st. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $391.80.

Insider Buying and Selling

In related news, EVP James Barry sold 623 shares of the company's stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $330.49, for a total value of $205,895.27. Following the completion of the sale, the executive vice president now owns 147 shares in the company, valued at approximately $48,582.03. This represents a 80.91 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, COO Andrew J. Last sold 3,000 shares of the firm's stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $329.94, for a total value of $989,820.00. Following the transaction, the chief operating officer now owns 7,559 shares in the company, valued at approximately $2,494,016.46. This trade represents a 28.41 % decrease in their position. The disclosure for this sale can be found here. 17.06% of the stock is currently owned by insiders.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.